Page last updated: 2024-12-11

2-(3,4-dimethoxyphenyl)-3-fluoroallylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(3,4-dimethoxyphenyl)-3-fluoroallylamine is a synthetic molecule that has been studied as a potential therapeutic agent for a range of diseases, including cancer and Parkinson's disease.

Here's why it's important for research:

**1. Potential Anticancer Activity:**

* **Inhibition of Tubulin Polymerization:** This molecule is known to inhibit the polymerization of tubulin, a protein crucial for the formation of microtubules. Microtubules are essential for cell division and other cellular processes. Disrupting microtubule function can lead to cell death, making this molecule a potential anticancer agent.

* **Targeting Cancer Cell Signaling Pathways:** Some studies suggest that 2-(3,4-dimethoxyphenyl)-3-fluoroallylamine might target specific signaling pathways involved in cancer cell growth and survival, making it a promising candidate for further investigation.

**2. Potential Treatment for Parkinson's Disease:**

* **Dopamine Release Enhancement:** This molecule has shown the ability to enhance dopamine release in the brain. Dopamine is a neurotransmitter vital for movement control. Parkinson's disease is characterized by a loss of dopamine-producing neurons, leading to movement disorders. Research explores whether this molecule could help restore dopamine levels and alleviate Parkinson's symptoms.

**3. Structure-Activity Relationships:**

* **Analogs and Derivatives:** Researchers often study the structure-activity relationships of molecules like this. By modifying the chemical structure, scientists can create analogs and derivatives that might have enhanced activity or fewer side effects. This approach helps to optimize the therapeutic potential of the molecule.

**4. Further Research:**

* **Preclinical Studies:** Significant research is needed to evaluate the safety and efficacy of 2-(3,4-dimethoxyphenyl)-3-fluoroallylamine in preclinical studies using animal models.
* **Clinical Trials:** If promising results emerge from preclinical research, clinical trials would be necessary to assess the molecule's safety and effectiveness in human patients.

**Important Note:** While research is promising, it's crucial to remember that 2-(3,4-dimethoxyphenyl)-3-fluoroallylamine is still in the early stages of development. Further research is required before it can be used as a safe and effective therapeutic agent.

2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: structure & RN from first source; RN given refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438383
CHEMBL ID445285
MeSH IDM0119470

Synonyms (10)

Synonym
mdl 72145
benzeneethanamine, beta-(fluoromethylene)-3,4-dimethoxy-, (e)-
2-(3,4-dimethoxyphenyl)-3-fluoroallylamine
2-dlpfa
2-(3,4-dimethoxyphenyl)-3-fluoroprop-2-en-1-amine
bdbm50261815
CHEMBL445285 ,
mdl-72145
85278-66-6
(e)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"5 ng/ml of tyramine in 1 ml of human plasma and is thus suitable for monoamine oxidase inhibitor studies involving oral dosing with tyramine."( Measurement of tyramine in human plasma, utilising ion-pair extraction and high-performance liquid chromatography with amperometric detection.
Brown, MJ; Causon, RC, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Membrane primary amine oxidase Rattus norvegicus (Norway rat)IC50 (µMol)0.00600.00600.50301.0000AID366637
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki231.00000.00192.379710.0000AID366634
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID366636Selectivity for human recombinant MAOB over human recombinant MAOA2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
AID366634Inhibition of human recombinant MAOA2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
AID366637Inhibition of rat CAO2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (59.26)18.7374
1990's9 (33.33)18.2507
2000's2 (7.41)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.71 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.70%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]